Toxic Epidermal Necrolysis research hub

New therapeutic approach to Toxic Epidermal Necrolysis (TEN) using anti-CD38+ antibodies in the active phase of the disease – Phase I/II study to assess the tolerance and efficacy of DARATUMUMAB - NET-CD38 Study

This study is testing a new medicine called daratumumab for a severe skin condition called Toxic Epidermal Necrolysis (TEN). We want to see if it's safe and helps people in the early stages of the disease. It's an early-stage study, open to adults.